Richardson's Syndrome: A Review of the Current Understanding of Progressive Supranuclear Palsy

The deposition of misfolded and neurotoxic forms of tau protein in particular regions of the cortex, basal ganglia, and midbrain causes progressive supranuclear palsy (PSP), a neurodegenerative disease. It is among the most typical types of tauopathy. Concurrent neurodegenerative illnesses frequently occur alongside PSP, which manifests in a variety of phenotypic variants. PSP is always fatal, and there are currently no proven effective disease-modifying treatments for it. Numerous tau-targeting therapeutic approaches have been studied and shown to be ineffective, including vaccinations, monoclonal antibodies, and microtubule-stabilizing drugs. There is an urgent need to treat PSP and other tauopathies, and numerous clinical trials looking into tau-targeted therapies are currently under progress. To gather data for this study, preclinical and clinical research on PSP treatment was retrieved from the PubMed database. In order to find previous and ongoing clinical trials pertinent to the treatment of PSP, a search was also conducted on the ClinicalTrials.-gov website of the US National Library of Medicine. Our findings on these papers, which cover possible disease-modifying medication trials, modifiable risk factor management, and symptom treatments, are compiled in this narrative review